Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibers
The very fact that we define results as positive or negative highlights our reluctance to accept change, that the story we have built in our heads may not fully reflect our reality
It seems there might be a trend away from crude and opportunistic tack-on merger and acquisition deals and toward more deliberate M&A deals that better fit companies' current and future needs, which would be welcome in an era when internal, organic R&D growth isn't what it used to be
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.